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Abstract
Background: Carbon labeled urea breath tests usually entail a two point sampling with a 20 to 30-minute gap.
Our aim was to evaluate the duration of time needed for diagnosing Helicobacter pylori by the BreathID
® System.
Methods: This is a retrospective multicenter chart review study. Test location, date, delta over baseline, and
duration of the entire test were recorded. Consecutively
13C urea breath tests results were extracted from the files
over a nine year period.
Results: Of the 12,791 tests results, 35.1% were positively diagnosed and only 0.1% were inconclusive. A statistically
significant difference in prevalence among the countries was found: Germany showing the lowest, 13.3%, and
Israel the highest, 44.1%. Significant differences were found in time to diagnosis: a positive diagnosis had the
shortest and an inconclusive result had the longest. Overall test duration averaged 15.1 minutes in Germany versus
approximately 13 minutes in other countries. Diagnosis was achieved after approximately 9 minutes in Israel, Italy
and Switzerland, but after 10 on average in the others. The mean delta over baseline value for a negative diagnosis
was 1.03 ± 0.86, (range, 0.9 - 5), versus 20.2 ± 18.9, (range, 5.1 - 159.4) for a positive one.
Conclusions: The BreathID
® System used in diagnosing Helicobacter pylori can safely shorten test duration on
average of 10-13 minutes without any loss of sensitivity or specificity and with no test lasting more than 21
minutes.
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Background
Among the non-endoscopic procedures used in diagnos-
ing Helicobacter pylori (H. pylori), serology remains the
most accepted. It is a widely available, inexpensive test
with a high negative predictive value. However, the vari-
able specificity, especially if the prevalence of H. pylori
is low, and its relatively poor positive predictive value,
limit the use of the test. Carbon labeled urea breath
tests (UBT), which have a high sensitivity and specificity,
are commonly used as a noninvasive method in detect-
ing an active Helicobacter pylori (H. pylori)i n f e c t i o n .
UBT are the preferred method used in epidemiological
studies, screening dyspeptic patients and assessing
eradication or recurrence of the infection [1]. These
tests usually entail a two point sampling with a 20 to
30-minute gap, and necessitate a mass spectrometry for
analysis. Upon modifying the sampling method, immedi-
ate results can be achieved.
One such option includes real time continuous sam-
pling
13C molecular correlation spectroscopy (MCS™)
technology. The BreathID
® device (Exalenz, Israel) has
been validated and cleared by the FDA and has also
been previously used on children and adults [2,3]. This
office-based system offers several advantages over the
conventional mass spectrometry-based UBT, including
an immediate test result, a standardized test drink (citric
acid) and, most importantly for children, a sampling
method that does not require active cooperation.
For many years, test shortening procedures have been
routinely practiced including the use of various
13C-urea
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new molecular correlation spectrometry technology
enables continuous sampling of the expired breath of
the patients, which in turn, enables the device to termi-
nate the test immediately after a conclusive positive or
negative result of H. pylori had been identified [2].
The use of a citric acid-based test drink has been
shown to enhance hydrolysis of the urea and produce a
more rapid rise in expired
13CO2 [4]. The BreathID™-
system combined with a citric acid drink and continu-
ous breath sampling significantly reduces the amount of
time needed for a final result compared to isotope ratio
mass spectrometer. However, these test-shortening
modifications have not been widely accepted by the
medical community. There are limited data [5] validat-
ing these tests but they have been in use in several gas-
troenterology departments for many years.
The current investigation retrospectively examined
over 12,000 BreathID™ test results from several ran-
domly selected gastroenterology departments. The goal
of this retrospective evaluation was to assess, on average,
the minimal time required to achieve accurate, definite
UBT results using the BreathID™ system.
Methods
Urea Breath Tests
The effect of the breath test sampling method in detect-
ing H. pylori was examined using continuous real time
methodology (i.e., the BreathID
® system). The
BreathID™ system is comprised of the following com-
ponents: a) a kit containing 75 mg of
13C-urea (a 99%
13C-enriched urea tablet); b) a packet of granulated
Citrica (a 4.5 gram packet containing 4 g of citric acid,
0.149 mg of aspartame, orange aroma, FD&C yellow
#6); c) an IDcircuit-sampling device; and d) a BreathID
®
device. All patients received 75 mg of
13C-urea with a
4.5 gram citric acid based powder (Citrica). The IDcir-
cuit, a continuous nasal breath sampling device, trans-
ported the breath sample from the patient to the
BreathID™ and did not require active cooperation.
Based on molecular correlation spectrometry, the
BreathID
® continuously measured
13CO2 and
12CO2
concentrations from the patient’s breath, thus establish-
ing the
13CO2/
12CO2 ratio, displayed vs. time on the
screen. The results were obtained within 10-15 minutes
and printed on a thermal printer.
Determining the positive or negative results from the
BreathID™ was based on a device algorithm. If, after 5
minutes, the delta over baseline (DOB) of the
13CO2/
12CO2 ratio was greater than 6 at more than two time
points, the patient was considered positive. If, after 5
minutes, the DOB was below 3 at more than two time
points, the patient was considered negative. If, after 20
minutes, neither of the two criteria was fulfilled, then
the nominal 5 DOB threshold was considered in order
to distinguish positive from negative patients, unless the
previous three points were within ± 1 DOB of the 5
DOB threshold. In this case, the results were defined as
inconclusive.
The study protocol was approved by the Institutional
Review Board of the Rabin Medical Center. Informed
consent was not taken from all patients since this is ret-
rospective study with data taken from different centers
not all needing informed consent. The study was sup-
ported by Exalenz, Ltd.
Study Subjects and Protocol
A total of 12,751 consecutively selected
13C urea breath
tests performed between 2001 and 2009 were extracted
from the files of fifteen gastrointestinal units in Israel, The
Netherlands, Switzerland, Germany and Italy, representing
approximately 50% of the tests performed during the 9-
year period. Some patients underwent a second UBT test
after H. pylori eradication. For subjects who had more
than one test result, pre and post treatment, all of the
identified tests were used. There was no obvious selection
bias, as all tests were collected from these centers.
13C-
UBT in the gastroenterology clinical laboratories was used
in subjects with gastrointestinal symptoms, such as dys-
pepsia, peptic ulcers and gastric malignancy. UBT was
given to patients after a three-hour fast.
Exclusion criteria included: a) administration of anti-
biotics and/or bismuth preparations within four weeks
prior to date of entry to the study; b) administration of
proton pump inhibitors within 2 weeks prior to date of
entry to the study; and c) pregnant or breast-feeding
women. The challenges were separated into positive
(DOB > 5 within 20 minutes) and negative test results
(DOB < 5 within 20 minutes). Test date, country, device
number, DOB, final result time (time at which the test
result was obtained) and duration of the entire test were
recorded. In addition, we specifically searched for the
number of individuals who had an inconclusive result
after 20 minutes (within 1 DOB of the threshold, as
described above).
Statistical Analyses
Continuous variables are summarized by mean, standard
deviation (SD), minimum, median and maximum and
are compared by a t-test (two groups) or ANOVA (3
groups or more). Categorical variables are summarized
by a count and percentage and compared by a chi-
squared test. Since so few tests were inconclusive, sub-
jects with inconclusive results were excluded from the
analyses. In addition, there were 27 test subjects for
whom duration of examination was incorrectly recorded
due to a software bug. Therefore, these cases were also
excluded from analyses of test duration.
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Prevalence of H. pylori
The diagnosis distribution was evaluated in all sites
within each country. Italy - 7, Israel - 5 and Germany,
The Netherlands and Switzerland, with only one site
each. All sites had one device per site except for Swit-
zerland, with two.
Study data are presented in Table 1. Out of 12,751
tests performed (Table 1), only 0.1% of the test results
were inconclusive. Analysis of the H. pylori prevalence
by country revealed a statistically significant difference
in prevalence among the countries evaluated in the
study. Germany had the lowest prevalence with 13.3%
and Israel the highest with 44.1% (Table 2).
Duration of the Testing Procedure
The duration of the test procedure from initiation until
completion (overall test duration) and the amount of
time required until the device was able to provide a
diagnosis (test duration until diagnosis) was compared.
We found significant differences in both overall duration
and time to diagnosis obtained among the three possible
outcomes: positive, negative and inconclusive: a positive
diagnosis had the shortest duration and an inconclusive
result had the longest duration (Table 1). Significant dif-
ferences in both overall duration and time to diagnosis
between the countries were also found.
Overall, test duration was 15.1 minutes in Germany
versus approximately 13 minutes in other countries.
This may have been due to the low prevalence of H.
pylori in Germany (Table 2) which lead to a longer test
duration (Table 3). Diagnosis was obtained after
approximately 9 minutes in Israel, Italy and Switzerland,
but after 10 minutes in The Netherlands and Germany.
Significant differences in both overall duration and time
to diagnosis among the sites were also demonstrated,
where the shortest mean overall test duration was 12.7
minutes in Italy versus approximately 15 minutes in
Israel and Germany. Diagnosis was obtained after
approximately 9 minutes in three Israeli sites, one Ita-
lian site and a little over 10 minutes on average in The
Netherlands, Germany and two Italian sites. Similar
results were obtained between devices within their
respective countries, which may validate the differences
as country- related and not device- related.
No significant differences were found in overall test
duration between tests performed in the morning (until
4 pm) versus tests performed in the afternoon/evening
(4 pm or later).
Delta Over Baseline Values (DOB)
Diagnosis, given by the BreathID™ device, was derived
by evaluating the DOB value. The mean DOB value for
a negative diagnosis was 1.03 (± 0.86) with a range of
0.9 to 5, whereas the positive cases had a mean DOB of
20.2 (± 18.9) and a range of 5.1 through 159.4. Greater
variability was seen in DOB means between countries
for positively diagnosed subjects than for negative sub-
jects, although this difference was not statistically signifi-
cant (Table 1).
Discussion
The optimal
13C-UBT conditions for diagnosing H.
pylori infection are still being perfected. Attempts to
improve the
13C-UBT have focused on decreasing the
amount of substrate used and reducing the duration of
the test. Urita et al. recently reported an ultra short ten
second endoscopic UBT using 20 mg of
13C-urea
sprayed onto the gastric mucosa. The maximum sensi-
tivity and specificity of intragastric samples were 83.7%
and 100% with a cut-off point of 8 per thousand. How-
ever, their clinical cohort cannot be compared with ours
because of the use of an invasive endoscopic method [6].
No consensus was demonstrated in the evaluation of
different
13C-UBT protocols regarding the dosage of the
13C-urea, the time and interval of the breath sample col-
lection or the test meal chosen to delay gastric empty-
ing. Each clinical center used its own test protocol,
Table 1 Distribution of test duration and DOB by diagnosis.
Outcome N (%) Distribution by test duration (n = 12,724)*
Mean ± SD
(Minutes)
Minimum
(Minutes)
Median
(Minutes)
Maximum
(Minutes)
Inconclusive 8 (0.1) 18.04 ± 1.76 14.68 18.09 20.35
Negative 8254 (64.8) 10.03 ± 2.24 5.43 10.05 20.58
Positive 4462 (35.1) 8.93 ± 2.55 5.42 8.02 20.90
Outcome N (%) Distribution of DOB by diagnosis (n = 12751)
Mean ± SD Minimum Median Maximum
Inconclusive 8 (0.1) 5.50 ± 0.24 5.20 5.55 5.80
Negative 8268 (64.8) 1.03 ± 0.86 -0.90 1.00 5.00
Positive 4475 (35.1) 20.20 ± 18.89 5.10 13.20 159.4
*(There were 27 tests without duration results, only DOB results (as mentioned in the paper).
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Although Dominguez-Munoz et al. reported identical
sensitivity and 100% specificity of
13C-UBT for three dif-
ferent test meals (0.1 N citric acid solution, semiliquid
fatty meal and semiliquid meal), the delta peak values of
13CO2 were much higher when a citric acid solution was
used as the test drink [7]. Moreover, Graham et al. using
1, 2 and 4 g of citric acid reported that the increase in
urease activity was dose dependent [8].
In general, acidic gastric milieu may improve the accu-
racy of the UBT, probably by increasing the entrance of
urea into H. pylori and the activity of its cytoplasmic
urease, the cornerstone of the urea breath test [9-12].
Acidic gastric juices may also neutralize the ammonia,
which may cause bacterial damage by itself and reduce
urease activity [13].
A higher acidic gastric environment (pH approxi-
mately 2.0) induced by citric acid has been found by
several investigators to increase the exhaled CO2 iso-
topes (
13Co r
14C) levels in a dose dependent manner
[4,7,8]. To maintain a low gastric pH, we used high dose
citric acid, which also delays gastric emptying [14].
However, others have hypothesized that these two fac-
tors appear unlikely to be the critical determinants in
the increased access of urea to the urease enzyme in
vivo [15-17].
Hamlet et al. more than a decade ago, examined the
efficacy and duration of
14C-UBT using similar methods
[18,19]. They reported that by supplying
14C-urea as a
rapid -release tablet along with citric acid, it is possible
to shorten the duration of the UBT to 10 minutes with
excellent accuracy, even during acid suppression ther-
apy. The tablet-based UBT proved to be accurate during
omeprazole treatment, correctly identifying all of the 10
H. pylori-infected patients [19].
Chey et al. and our group also demonstrated that
intragastric acidification by citrate administration before
and during the UBT decreased the false negative results
in patients receiving PPI treatment [20-22]. The
decreased false negative results induced by PPIs are
probably related to the use of citric acid as a test drink.
Thus, the data reported by Hamlet et al. are consistent
with our data.
An acknowledged weakness of our study was the
absence of a gold standard to evaluate the performance
of the BreathID
® system. However, the device was
approved by the FDA in 2001, making it a comparable
test to endoscopy in diagnosing H. pylori. (The valida-
tion trial can be reviewed at link: http://www.accessdata.
fda.gov/cdrh_docs/pdf/k011668.pdf).
Since our data is based on raw data from the devices,
demographic data is unavailable. The impact of this
office- based, fully automated breath collection system,
showing immediate results, is that it is activated by a
single button, with no need of entering other patient
data. Nevertheless, the patient’s name/ID can be added
to the printout.
Conclusions
The BreathID
® test used in our research, performed
with a continuous breath test sampling device, collected
data from 5 countries over a period of 9 years. Our ana-
lysis of 12,791 randomly chosen BreathID™ tests using
ah i g hd o s ec i t r i ca c i da sat e s td r i n ka n dc o n t i n u o u s
sampling of the expired breath indicated that comple-
tion of the UBT required 10-13 minutes on average.
Only 8 subjects (0.1%) from the total population had
inconclusive results and needed further time to reach a
conclusive result. Our results are in agreement with an
earlier report using the same technique on a smaller
group of examinees [5]. Although this study is
Table 3 Distribution by country of total test duration and test duration until diagnosis
Test duration (min) Test duration until diagnosis (min)
Test duration by country N Mean SD Minimum Median Maximum N Mean SD Minimum Median Maximum
Country
Germany 195 15.10 4.18 10.43 14.48 32.77 195 10.24 2.43 6.68 10.25 20.18
Netherland 2198 13.36 2.97 6.63 12.95 41.40 2198 10.46 2.58 5.42 10.26 20.48
Israel 5918 13.13 3.18 8.18 12.05 47.12 5918 9.23 2.20 5.62 8.25 20.48
Italy 3853 12.97 3.25 8.17 11.68 55.37 3853 9.78 2.47 5.62 8.65 20.90
Switzerland 552 13.80 4.01 8.53 12.94 33.28 552 9.59 2.47 6.12 8.83 20.38
P value < 0.0001 < 0.0001
Table 2 H. pylori prevalence by country
Diagnosis
Country Negative Positive All
N%N%
Germany 169 86.7 26 13.3 195
Netherland 1671 76.0 529 24.0 2200
Israel 3322 55.9 2619 44.1 5941
Italy 2701 70.1 1154 29.9 3855
Switzerland 405 73.4 147 26.6 552
P value* < 0.0001
*Between countries
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validation of the usefulness of BreathID
® as a short and
rapid method in diagnosing H. pylori.
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